How European countries prevent and communicate on Hantavirus infection, ECDC study
Prompted by the increase of hantavirus activity in Europe observed in 2012, ECDC report reviewed the preventive measures and communication strategies in European countries.
Surveillance, prevention and control of dengue in Madeira: lessons learnt after the 2013 ECDC mission
New report provides recommendations for surveillance, prevention and control of dengue in Madeira, following the ECDC mission to Madeira in March 2013.
New ECDC protocols for surveillance of healthcare-associated infections: targeted surveillance is an essential tool for control and prevention
Today, ECDC’s Healthcare-associated Infections Surveillance Network (HAI-Net) publishes a new version of the software application HelicsWin.Net.
Investing in HIV response essential to curb on-going HIV transmission in Europe.Archived
New data for 2011 show that more than 121 000 new HIV cases were reported in the WHO European Region, including more than 28 000 new infections in the European Union and the European Economic Area (EU/EEA), indicating an increase for the whole Region compared to the previous year1.
Taking stock: where does Europe stand in the elimination of hepatitis B and C?
In 2016, a regional action plan for Europe that aims to contribute to the implementation of the global viral hepatitis elimination strategy was developed by the WHO Regional Office for Europe. In an article published today in Eurosurveillance, the authors take a closer look how Europe is doing according to the ten indicators and targets outlined in this plan. In short: Europe still has some way to go if it wants to eliminate viral hepatitis by 2030.
Expert panel reviews neuraminidase inhibitors for the prevention and treatment of influenza
An ECDC expert opinion concludes that there is clear evidence supporting the use of neuraminidase inhibitors in the treatment and prevention of influenza. Moreover, the current recommendations in European countries on the use of the neuraminidase inhibitors oseltamivir and zanamivir are appropriate and should be applied by prescribing physicians.
1 in 7 people living with HIV in the EU/EEA are not aware of their HIV status
Almost 30 000 newly diagnosed HIV infections were reported by the 31 European Union and European Economic Area (EU/EEA) countries in 2015, according to data published by ECDC and the WHO Regional Office for Europe. This is similar to the observed notification trends in the last decade. One reason for this persistent HIV epidemic: ECDC estimates that currently around 122 000 people living with HIV across the region are unaware of their infection. The estimated time between HIV infection and diagnosis is four years.
Marking European Testing Week: ECDC issues integrated hepatitis and HIV testing Guidance
To mark European Testing Week from 23 to 30 November 2018, ECDC publishes its new Guidance on integrated viral hepatitis and HIV testing.
HIV in Europe and Central Asia: progress in 2018 towards meeting the UNAIDS 90-90-90 targets
In 2014, the Joint United National Programme on HIV/AIDS (UNAIDS) established the global 90–90–90 targets. The aim was for 90% of all people living with HIV (PLHIV) to be diagnosed, 90% of those diagnosed to receive antiretroviral treatment (ART) and 90% of those receiving treatment to achieve viral suppression, by 2020. This article describes progress towards the UNAIDS 90–90–90 targets across Europe and Central Asia and discuss whether current performance is sufficient to eliminate HIV transmission.